Strategic Focus Treadwell Therapeutics is a clinical-stage biotechnology company focused on highly aggressive cancers with novel targets such as aneuploidy and immunogenicity, indicating opportunities to position partnerships around first-in-class small molecule therapeutics and combination regimens.

Lead Programs Core assets include CFI-400945 (PLK4 inhibitor) in multiple Phase 1/2 trials, and CFI-402257 (TTK inhibitor), with a preclinical HPK1 inhibitor (CFI-402411) poised to enter clinical stages; potential for license deals, co-development, or strategic collaborations to accelerate clinical development.

Regulatory Expertise Recent expansion in regulatory leadership with Brenda Marczi appointed SVP and Head of Regulatory Affairs, signaling readiness to advance regulatory filings and enable faster progression through trials, a cue for CROs, regulatory consultants, and partnering discussions.

Clinical events Active presence at major hematology and immunotherapy conferences (ASH, SITC, SABCS) demonstrates ongoing data dissemination and visibility; opportunities to engage investigators, potential alliance talks, and sponsor collaborations around presenting trial updates and patient access programs.

Funding and Scale Funded with about $91M and revenue in the $1M–$10M range, suggesting appetite for strategic collaborations, co-funding, or milestone-based partnerships to de-risk development costs while expanding clinical programs and potential geographic expansion.